Holen Sie sich die Stockscreener-App
14.62
2.21%
-0.33
Vorhandelsmarkt:
14.91
0.29
+1.98%
Schlusskurs vom Vortag:
$14.95
Offen:
$14.55
24-Stunden-Volumen:
13,164
Relative Volume:
0.32
Marktkapitalisierung:
$792.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-143.59M
KGV:
-5.1778
EPS:
-2.8236
Netto-Cashflow:
$-119.47M
1W Leistung:
-6.10%
1M Leistung:
-4.57%
6M Leistung:
-18.28%
1J Leistung:
-34.41%
1-Tages-Spanne:
$14.53
$15.18
1-Wochen-Bereich:
$14.50
$16.14
52-Wochen-Spanne:
$14.14
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
Vergleichen Sie PHVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
14.62 | 792.89M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Where are the Opportunities in (PHVS) - Stock Traders Daily
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris: Despite 30% Decline, Still Fair At Best (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest - MarketBeat
Trend Tracker for (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS) - MarketBeat
Learn to Evaluate (PHVS) using the Charts - Stock Traders Daily
Pharvaris (PHVS) Price Target Increased by 38.65% to 32.93 - MSN
Pharvaris price target lowered to $46 from $50 at JMP Securities - Yahoo Finance
Long Term Trading Analysis for (PHVS) - Stock Traders Daily
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):